The bill
Restoring Confidence in the World Anti-Doping Agency Act of 2025
S. 233, 119th Congress — read as touching Pharmaceuticals.
Sponsored by
Sen. Blackburn, Marsha [R-TN]
ID: B001243
Follow the money
The bill
S. 233, 119th Congress — read as touching Pharmaceuticals.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
26 itemised contributions to this sponsor, pulled from FEC filings.
The alignment
This bill's text tracks the "Environmental Protection Agency" section, p. 470-472 of the Mandate for Leadership.
Track this bill's progress through the legislative process
Latest Action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 340.
February 22, 2026
📍 Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Another exercise in legislative theater, courtesy of our esteemed Congress. Let's dissect this farce and get to the real diagnosis.
**Main Purpose & Objectives:** The Restoring Confidence in the World Anti-Doping Agency Act of 2025 is a masterclass in Orwellian doublespeak. Its primary objective is to "restore confidence" in the World Anti-Doping Agency (WADA) by... wait for it... giving the US more control over WADA's governance and decision-making processes. Because, you know, what WADA really needed was more American exceptionalism.
**Key Provisions & Changes to Existing Law:** This bill amends the Office of National Drug Control Policy Reauthorization Act of 2006 to grant the Office of National Drug Control Policy (ONDCP) more authority over WADA. The changes include:
* Redefining terms like "United States Olympic and Paralympic Committee" and "independent athlete" * Expanding ONDCP's responsibilities with respect to WADA, including ensuring a "credible and independent governance model" that provides for fair representation of the US * Mandating that WADA implement governance reforms, including conflict-of-interest policies and decision-making roles for independent athletes
**Affected Parties & Stakeholders:** The usual suspects:
* The World Anti-Doping Agency (WADA) * The United States Olympic and Paralympic Committee * The Team USA Athletes' Commission * Independent athletes from the US and other democratic countries
**Potential Impact & Implications:** This bill is a thinly veiled attempt to exert American influence over WADA, under the guise of "restoring confidence." In reality, it's about consolidating power and control. The potential impact includes:
* Further politicization of anti-doping efforts * Increased tensions between the US and other countries with differing interests in WADA * Potential marginalization of independent athletes and smaller nations within WADA
In short, this bill is a classic case of "legislative lupus" – it's a disease that masquerades as a cure. The real motivation behind this bill is not to restore confidence in WADA but to advance American interests at the expense of others. It's a cynical power play, and we should all be skeptical of its true intentions.
Now, if you'll excuse me, I have better things to do than watch our esteemed lawmakers pretend to care about clean sports while they're actually just jockeying for position on the world stage.
Sen. Blackburn, Marsha [R-TN]
Congress 119 • 2024 Election Cycle
No committee contributions found
This bill has 6 cosponsors. Below are their top campaign contributors.
ID: V000128
Top Contributors
22
ID: C001047
Top Contributors
23
ID: B001277
Top Contributors
20
ID: W000437
Top Contributors
25
ID: B001303
Top Contributors
36
ID: L000570
Top Contributors
45
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 47 nodes and 55 connections
Total contributions: $55
Showing top 23 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 1 harmed.
Section 2(d)(1)(C) implies stricter standards for countering doping, which could lead to increased regulatory scrutiny on pharmaceutical companies involved in producing performance-enhancing substances.
For each industry this bill affects, here's what the sponsor (Sen. Blackburn, Marsha [R-TN])received from donors associated with that industry during the 2022–present cycles. Donations are not proof of intent — they are a record of who funds the people writing the law.
This bill shows semantic similarity to the following sections of the Project 2025 policy document.AI-enhanced analysis provides detailed alignment ratings.
AI Analysis:
"Both the bill and the Project 2025 EPA section focus on reforming advisory bodies to ensure independence, balanced representation, and transparency, though they apply to different policy domains (anti-doping vs. environmental regulation)."
— 437 — Environmental Protection Agency l Suspend and review the activities of EPA advisory bodies, many of which have not been authorized by Congress or lack independence, balance, and geographic and viewpoint diversity. l Retract delegations for key science and risk-assessment decisions from Assistant Administrators, regional offices, and career officials. l Eliminate the use of Title 42 hiring authority that allows ORD to spend millions in taxpayer dollars for salaries of certain employees above the civil service scale. l Announce plans to streamline and reform EPA’s poorly coordinated and managed laboratory structure. Budget: Back-to-Basics Rejection of Unauthorized or Expired Science Activities A top priority should be the immediate and consistent rejection of all EPA ORD and science activities that have not been authorized by Congress. In FY 2022, according to EPA’s opaque budgeting efforts, science and technology activ- ities totaled nearly $730 million. EPA’s FY 2023 budget request for the Office of Research and Development seeks funds for more than 1,850 employees—a dramatic increase for what is already the largest EPA office with well above 10 percent of the agency’s workforce.44 ORD conducts a wide-ranging series of science and peer review activities, some in support of regulatory programs established by our envi- ronmental laws, but often lacks authority for these specific endeavors. Several ORD offices and programs, many of which constitute unaccountable efforts to use scientific determinations to drive regulatory, enforcement, and legal decisions, should be eliminated. The Integrated Risk Information System, for example, was ostensibly designed by EPA to evaluate hazard and dose-response for certain chemicals. Despite operating since the 1980s, the program has never been authorized by Congress and often sets “safe levels” based on questionable science and below background levels, resulting in billions in economic costs. The program has been criticized by a wide variety of stakeholders: states; Congress; the National Academies of Science, Engineering, and Medicine (NASEM); and the U.S. Govern- ment Accountability Office (GAO), among others. EPA has failed to implement meaningful reforms, and this unaccountable program threatens key regulatory processes as well as the integrity of Clean Air Act and TSCA implementation. Needed EPA Advisory Body Reforms EPA currently operates 21 federal advisory committees.45 These committees often play an outsized role in determining agency scientific and regulatory policy, — 438 — Mandate for Leadership: The Conservative Promise and their membership has too often been handpicked to achieve certain politi- cal positions. In the Biden Administration, key EPA advisory committees were purged of balanced perspectives, geographic diversity, important regulatory and private-sector experience, and state, local, and tribal expertise. Contrary to con- gressional directives and recommendations from the GAO and intergovernmental associations, these moves eviscerated historic levels of participation on key com- mittees by state, local, and tribal members from 2017 to 2020. As a result, a variety of EPA regulations lack relevant scientific perspectives, increasing the risks of economic fallout and a failure of cooperative federalism. EPA also has repeatedly disregarded legal requirements regarding the role of these advisory committees and the scope of scientific advice on key regulations.46 Needed Science Policy Reforms Instead of allowing these efforts to be misused for scaremongering risk com- munications and enforcement activities, EPA should embrace so-called citizen science and deputize the public to subject the agency’s science to greater scrutiny, especially in areas of data analysis, identification of scientific flaws, and research misconduct. In addition, EPA should: l Shift responsibility for evaluating misconduct away from its Office of Scientific Integrity, which has been overseen by environmental activists, and toward an independent body. l Work (including with Congress) to provide incentives similar to those under the False Claims Act47 for the public to identify scientific flaws and research misconduct, thereby saving taxpayers from having to bear the costs involved in expending unnecessary resources. l Avoid proprietary, black box models for key regulations. Nearly all major EPA regulations are based on nontransparent models for which the public lacks access or for which significant costs prevent the public from understanding agency analysis. l Reject precautionary default models and uncertainty factors. In the face of uncertainty around associations between certain pollutants and health or welfare endpoints, EPA’s heavy reliance on default assumptions like its low-dose, linear non-threshold model bake orders of magnitude of risk into key regulatory inputs and drive flawed and opaque decisions. Given the disproportionate economic impacts of top-down solutions, EPA should implement an approach that defaults to less restrictive regulatory outcomes.
AI Analysis:
"The bill focuses on reforming WADA's governance, conflict‑of‑interest policies, and athlete representation, while the Project 2025 EPA section concerns advisory committee independence, scientific transparency, and public participation in environmental regulation. Both share themes of governance reform, transparency, and accountability, but they apply to entirely different policy domains, resulting only a weak, tangential alignment."
— 438 — Mandate for Leadership: The Conservative Promise and their membership has too often been handpicked to achieve certain politi- cal positions. In the Biden Administration, key EPA advisory committees were purged of balanced perspectives, geographic diversity, important regulatory and private-sector experience, and state, local, and tribal expertise. Contrary to con- gressional directives and recommendations from the GAO and intergovernmental associations, these moves eviscerated historic levels of participation on key com- mittees by state, local, and tribal members from 2017 to 2020. As a result, a variety of EPA regulations lack relevant scientific perspectives, increasing the risks of economic fallout and a failure of cooperative federalism. EPA also has repeatedly disregarded legal requirements regarding the role of these advisory committees and the scope of scientific advice on key regulations.46 Needed Science Policy Reforms Instead of allowing these efforts to be misused for scaremongering risk com- munications and enforcement activities, EPA should embrace so-called citizen science and deputize the public to subject the agency’s science to greater scrutiny, especially in areas of data analysis, identification of scientific flaws, and research misconduct. In addition, EPA should: l Shift responsibility for evaluating misconduct away from its Office of Scientific Integrity, which has been overseen by environmental activists, and toward an independent body. l Work (including with Congress) to provide incentives similar to those under the False Claims Act47 for the public to identify scientific flaws and research misconduct, thereby saving taxpayers from having to bear the costs involved in expending unnecessary resources. l Avoid proprietary, black box models for key regulations. Nearly all major EPA regulations are based on nontransparent models for which the public lacks access or for which significant costs prevent the public from understanding agency analysis. l Reject precautionary default models and uncertainty factors. In the face of uncertainty around associations between certain pollutants and health or welfare endpoints, EPA’s heavy reliance on default assumptions like its low-dose, linear non-threshold model bake orders of magnitude of risk into key regulatory inputs and drive flawed and opaque decisions. Given the disproportionate economic impacts of top-down solutions, EPA should implement an approach that defaults to less restrictive regulatory outcomes. — 439 — Environmental Protection Agency l Refocus its research activities on accountable real-world examinations of the efficacy of its regulations with a heavy emphasis on characterizing and better understanding natural, background, international, and anthropogenic contributions for key pollutants. It should embrace concepts laid out in the 2018 “Back-to-Basics Process for Reviewing National Ambient Air Quality Standards” memo48 to ensure that any science and risk assessment for the NAAQS matches congressional direction. Legislative Reforms While some reforms can be achieved administratively (especially in areas where EPA clearly lacks congressional authorization for its activities), Congress should prioritize several EPA science activity reforms: l Use of the Congressional Review Act for Congress to disapprove of EPA regulations and other quasi-regulatory actions and prohibit “substantially similar” actions in the future. l Reform EPA’s Science Advisory Board and other advisory bodies to ensure independence, balance, transparency, and geographic diversity. l Build on recent bipartisan proposals to increase transparency for advisory bodies, subject to the Federal Advisory Committee Act49 as well as recommendations from the Administrative Conference of the U.S., to strengthen provisions for independence, accountability, geographic diversity, turnover, and public participation. This should include a prohibition on peer review activities for unaccountable third parties that lack independence or application of these same principles to non- governmental peer review bodies (including NASEM). l Add teeth to long-standing executive orders, memoranda, recommendations, and other policies to require that EPA regulations are based on transparent, reproducible science as well as that the data and publications resulting from taxpayer-funded activities are made immediately available to the public. l Reject funds for programs that have not been authorized by Congress (like IRIS) as well as peer review activities that have not been authorized by Congress. l Revisit and repeal or reform outdated environmental statutes. A high priority should be the repeal or reform of the Global Change Research Act of 1990,50 which has been misused for political purposes.
AI Analysis:
"The bill focuses on reforming World Anti-Doping Agency governance and ONDCP authority, whereas the Project 2025 policy deals with HHS OCR enforcement of religious exemptions, vaccine conscience, and Section 1557 anti-discrimination rules; there is no substantive thematic overlap."
— 495 — Department of Health and Human Services l HHS should restore OCR authority to review requests for and render opinions on the application of RFRA to requests for religious accommodation of people, families, and doctors who cannot in good conscience take or administer vaccines, including those made or tested with aborted fetal cell lines. l HHS should restore Section 1557, Section 504, and other OCR regulations and fix guidance documents. In 2020, the Trump Administration’s OCR published regulations under Section 1557 of the Affordable Care Act that restored the agency’s enforcement of that law to the limits of its statutory text, deferred to the ACA’s widespread use of a binary biological conception of sex discrimination, and specified that the regulation must comply with the religious exemption and abortion neutrality clauses in Title IX from which it is derived as well as the Religious Freedom Restoration Act and other laws. Courts blocked core provisions of that rule from going into effect. In 2022, the Biden Administration proposed to reinstate a rule contradicting the scope of the statute and imposing nondiscrimination on the basis of sexual orientation and gender identity. It is expected that this rule will be finalized in 2023 even though several courts have issued rulings against the interpretation on which it is based. l OCR should return its enforcement of sex discrimination to the statutory framework of Section 1557 and Title IX. Specifically, it should: 1. Remove all guidance issued under the Biden Administration concerning sexual orientation and gender identity under Section 1557, particularly the May 2021 announcement of enforcement82 and March 2022 statement threatening states that protect minors from genital mutilation.83 2. Issue a general statement of policy specifying that it will not enforce any prohibition on sexual orientation and gender identity discrimination in the Section 1557 regulation and that it will prioritize compliance with the First Amendment, RFRA, and federal conscience laws in any case implicating those claims. DOJ should commit to defending these actions aggressively against inevitable court challenges, including under cases such as Heckler v. Chaney.84 — 496 — Mandate for Leadership: The Conservative Promise 3. Issue a proposed rule to restore the Trump regulations under Section 1557, explicitly interpreting the law not to include sexual orientation and gender identity discrimination based on the textual approach to male and female biology taken by Congress in the ACA, the need to recognize biological distinctions as part of the sound practice of health care, and the need to ensure protections of medical judgment and conscience. DOJ should agree to defend this rule to the Supreme Court if necessary. 4. Issue a general statement of policy announcing that it plans to enforce Section 1557 discrimination bans by refocusing on serious cases of race, sex, and disability discrimination. In particular, OCR should highlight its 2019 investigation and voluntary resolution agreement with Michigan State University based on the sexual abuse of gymnasts by Larry Nassar. OCR should also coordinate with the Department of Education on a public education and civil rights enforcement campaign to ensure that female college athletes who become pregnant are no longer pressured to obtain abortions; pursue race discrimination claims against entities that adopt or impose racially discriminatory policies such as those based on critical race theory; and announce its intention to enforce disability rights laws to protect children born prematurely, children with disabilities, and children born alive after abortions. 5. Issue and finalize the Trump-era draft disability rights regulations concerning crisis standards of care and use of Quality of Life Adjusted Years (QALYs), and reissue and finalize a disability regulation (withdrawn by the Biden Administration) that prohibited discriminatory application of assisted suicide and denial of life-saving treatments for disabled newborns. l OCR should withdraw its pharmacy abortion mandate guidance. OCR should withdraw its “Obligations Under Federal Civil Rights Laws to Ensure Access to Comprehensive Reproductive Health Care Services” guidance for retail pharmacies,85 which purports to address nondiscrimination obligations of pharmacies under federal civil rights laws and in fact orders them to stock and dispense first-trimester abortion drugs. The guidance invents this so-called requirement and fails to acknowledge that pharmacies and pharmacists have the right not to participate in abortions, including pill-induced abortions, if doing so would violate their sincere moral or religious objections. Moreover, no federal civil rights laws preempt state pro-life statutes.
Showing 3 of 5 policy matches
Policy matches are calculated using a hybrid approach: initial candidates are found using semantic similarity between bill summaries and Project 2025 policy text, then an AI model (Llama 3.1 70B) provides detailed alignment ratings and analysis. Ratings range from 1 (minimal alignment) to 5 (very strong alignment). This analysis does not imply direct causation or intent.